This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Pericosines are unique C7 cyclohexenoid metabolites of Periconia byssoides OUPS-N133 fungus that was originally isolated from the sea hare, Aplysia kurodai. Pericosines show significant in vitro cytotoxicity against P388 lymphocytic leukemia cells. Pericosine A, in particular, shows the most potent activity and significant in vivo antitumor activity against P388 cells. Thus, pericosines are promising candidates for seed compounds of anticancer drugs. However, before the total syntheses of pericosines were accomplished, their stereo structures could not be determined by spectral analyses because they have multi-functionalized cyclohexenoid structures with torsional strain. In this review, synthetic efforts for pericosines in this decade are surveyed.
Synthetic studies of carbasugars have been progressing on a worldwide scale [1–3]. Carbasugars are a class of carbocyclic analogues of monosaccharides in which oxygen atom in the ring is replaced with a carbon atom. Because of this, they are also called pseudo-sugars. Carbasugars exhibit gycosidase inhibitory, antitumor (including anticancer), antiviral, antifungal, antibacterial, and antimalarial activities. Therefore, the synthetic study of carbasugars is extremely important for the discovery of new drugs, including cancer preventive drugs. Mammals lack the shikimate pathway found in plants, fungi, microorganisms, and apicomplexan parasites. The chances of drug discovery are improved when shikimate analogues are focused on.
Figure 1 illustrates the structures of representative carbasugars as synthetic targets, including 2-crotonyloxy-(4R,5R,6R)-4,5,6-trihydroxy-cyclohex-2-enone (COCT) [4–15], [(−)-KD16-U1 [gabosine A [16–21], (+)-MK7607 [22, 23], (+)-valienamine [24–29], (+)-validamine [29–31], Relenza® [32], and Tamiflu® [33–40], COCT [41], (−)-KD16-U1 [42], and gabosines [43], which were isolated from cultures of Streptomyces spp., are potential glyoxalase inhibitors and therefore show promise as anticancer agents. (+)-MK7607, which was isolated from cultures of Curvularia eragrostidis D2452, showed herbicidal activity [44]. (+)-Valienamine and (+)-validamine were obtained from the degradation of antifungal antibiotic validamycin A by Pseudomonas denitrificans [45–47]. Valienamine is also a component of ascarbose, a potent α-glucosidase inhibitor [48].
Relenza and Tamiflu are the most popular anti-influenza drugs today and are therefore attractive target molecules for synthetic studies. Relenza is a potent anti-influenza drug designed from the transition structure of N-acetylneuramic acid-neuramidase complex based on X-ray analysis [32]. The oral anti-influenza drug Tamiflu has received immense attention for its effect on avian flu. To this day, however, the synthesis of Tamiflu remains an enigma for synthetic organic chemists. The independent asymmetric total synthesis of Tamiflu by Corey [35] and Shibasaki [36, 37] from non-natural starting material, which was published in JACS, was a hot topic in 2006. In 2007, Fukuyama and co-workers reported the practical synthesis of Tamiflu [38].
In the past several decades, scientists working on new drug discovery have extended their research field to include the ocean because of its vast biological/chemical diversity and the fact that it composes almost 70% of Earth’s surface. Marine natural products chemistry has produced a number of promising candidates for anticancer drugs and several of them have undergone pre- or phases I-III clinical trials [49, 50]. Recently, however, a new tide has emerged, which involves the study of metabolites of microorganisms from marine sources [51–53]. It must be emphasized that researchers involved in this endeavor have been attempting preservation of environmental habitat in the ocean. In 1997, Numata and co-workers isolated unique C7 cyclohexenoid-type metabolites from Periconia byssoides OUPS-N133 fungus that was originally isolated from the sea hare, Aplysia kurodai, and designated them as pericosines A 1 and B 2 (Figure 2), together with some macrospherides [54]. Full details of the isolation of pericosines A-E 1–5 were very recently reported by Numata and co-workers [55]. Pericosines showed significant in vitro cytotoxicity against P388 lymphocytic leukemia cells. Particularly, 1 was reported to have inhibitory activity against protein kinase and topoisomerase II in addition to significant in vivo antitumor activity against P388 cells. Thus, pericosines are thought to be promising candidates for seed compounds of anticancer drugs. However, total syntheses were required to confirm the stereo structures of most pericosines because the multi-functionalized cyclohexenoid structures with severe torsional strain have made structure determination by spectral analyses difficult. In this review, synthetic efforts to produce pericosines and analogues 1, 2, 4–7, and 9 from (−)-shikimic acid 10 or (−)-quinic acid 11 are surveyed comprehensively, together with the discovery of natural compounds.
2. Isolation of Pericosines from <italic>Periconia byssoides</italic> [<xref ref-type="bibr" rid="b54-ijms-09-00401">54</xref>, <xref ref-type="bibr" rid="b55-ijms-09-00401">55</xref>]
Numata and co-workers reported the isolation of C7 cyclohexenoids designated as pericosines A-E 1–5 in 1997 and 2007, as summarized below. The fungal strain P. byssoides OUPS-N133 was isolated from a culture of A. kurodai by bioactivity-guided cytotoxicity assay using P388 cells. The fungal strain was cultured in artificial seawater medium containing 1% malt extract, 1% glucose, and 0.05% peptone adjusted to pH 7.5 at 27°C. After 4 weeks, mycelia obtained by filtration of the broth were extracted with AcOEt. The AcOEt extract was separated by gel filtration through Sephadex LH-20 using MeOH-CH2Cl2 (1:1), followed by silica gel column chromatography with CH2Cl2-MeOH gradient solvent system. This separation was performed along with in vitro P388 cytotoxicity assay. The active fraction that was eluted with 10% MeOH-CH2Cl2 was further urified by reverse phase preparative HPLC using the MeOH-H2O solvent system to afford 1–5. Spectroscopic analyses including NMR, MS, and IR led to the elucidation of their structures. Early studies, however, indicated the structure of pericosine A as 6, that of pericosine C as 8, and that of pericosine D as 9 [56, 57]. It is difficult to determine the relative configuration of such compounds as pericosines because they possess a multi-functionalized cyclohexenoid core with torsional strain. In their most recent report, the authors stated that they elucidated the structures of pericosines, except for pericosine A, by spectroscopic analyses. They determined the relative chemistry of pericosine B 2 on the basis of NOE between H-3 and H-5 observed in its acetonide 2a and small coupling constants J3–4 = 5.7 Hz, J4–5 = 3.1 Hz, and J5–6 = 4.1 Hz. Long-range coupling between H-4/H-6, H-2/H-6, and H6/H-2 observed in 2a also supported their proposed configuration. Similar NOE between H-3 and H-5 and long-range coupling between H-2/H-6 and H-4/H-6 were observed in the spectra of 2, suggesting similar configuration. Pericosine C 3, which has the same planar structure as pericosine B 2, was transformed into acetonides 3a and 3b. Spectral analysis indicated that the 3,4,5-trihydroxyl groups on the cyclohexene ring had cis, cis configuration, and the stereochemistry at C-6 was determined to be different from that of 2. Finally, its identity was confirmed by comparing with synthesized compound 7. Interestingly, pericosine C exists as an enantiomeric mixture of 3 and 7, based on comparison of specific rotation values between natural pericosine C ([α]D25−4.8) and synthetic 7 ([α]D25+35.1). The relative chemistry of pericosine D 4 was determined on the basis of NOE between one acetonide-methyl/H-3, H-4 and another acetonide-methyl/H-5 observed in the NOESY spectrum of its 3,4-acetonide. The relative chemistry of pericosine E 5 was confirmed by X-ray analysis. Pericosine E 5 also exists as an enantiomeric mixture.
Pericosines are responsible for the cytotoxicity of the extract of P. byssoides. The ED50 values of pericosines are presented in Table 1. Compounds 1, 2, and 4 exhibited significant in vitro cytotoxicity against P388 cells. Most potent 1 also showed in vivo antitumor activity against P388 cells. Furthermore, 1 inhibited protein kinase EGFR and human topoisomerase II and showed selective growth inhibition against human cancer cell lines HBC-5 and SNB-75. Thus, pericosines were proved to be promising candidates for seed compounds of cancer preventive drugs.
3. Synthetic Efforts for Pericosines
As described above, the syntheses of pericosines are required not only to determine absolute configuration but also to confirm relative stereochemistry. The following are synthetic efforts by several groups carried out so far.
3.1. Total synthesis of pericosine B [<xref ref-type="bibr" rid="b58-ijms-09-00401">58</xref>]3.1.1. Donohoe’s approach
Donohoe and co-workers were the first to report the total synthesis of pericosine B (+)-2 in 1998. This is the only successful synthesis to date and has been achieved by using their original hydrogen-bond-directed dihydroxylation with osmium tetroxide to give cis, cis-triol. The synthesis is summarized in Scheme 1.
Commercially available (+)-dihydroxybromocyclohexadiene 12 was selectively protected to give silyl ether 13, which was then O-methylated with NaH and MeI and deprotected with TBAF to give alcohol 14. The subsequent hydrogen-bond-directed dihydroxylation of 14, which was the key step of this total synthesis, was carried out with stoichiometric osmium tetroxide and one equivalent of quinuclidine to give syn, syn- and syn, anti-triols, 15 and 16, in 2.2: 1 ratio. Separated 15 was protected with triethylsilyl (TES) groups to give 17, and 17 was methoxycarbonylated to yield 18. The synthesis was terminated by the addition of TFA to afford 2, which had the same spectroscopic data including specific rotation as those of the natural product, leading to the conclusion that the absolute stereochemistry is methyl (3S,4S,5S,6R)-3,4,5-trihydroxy-6-methoxycyclohexene-1-carboxylate. The problems of this synthesis included poor stereoselectivity in the crucial step and use of a stoichiometric amount of highly toxic osmium tetroxide.
Okamura and co-workers attempted the total synthesis of pericosine B also in 1998. The key reaction of their synthesis was the asymmetric Diels-Alder reaction of 3-hydroxy-2-pyrone 19 with a basic catalyst. Their synthetic approach is illustrated in Scheme 2.
The enantioselective Diels-Alder reaction between 3-hydroxy-2-pyrone 19 and acrylate with chiral auxiliary 20 was carried out in the presence of cinchonidine as basic catalyst to give endo-adduct 21 in 93% yield with 95% de. Adduct 21 was then treated with NaOMe to remove chiral auxiliary and the resultant methyl ester was dihydroxylated with catalytic osmium tetorxide and NMO to afford exo-diol, which was protected as benzylidene acetal 22. Reduction with LiAlH4 followed by treatment with NaIO4 gave diol 23, which was successively protected with a primary hydroxyl group such as TBS-ether followed by a secondary hydroxyl group such as pivaloyl ether to give ketone 24. Stereoselective reduction with NaBH4 afforded β-hydroxyalcohol, which was then O-methylated and deprotected with TBAF to give hydroxymethylether 25. Unfortunately, the completion of this synthesis from the intermediate has not been reported so far.
An approach taken by our group toward pericosine B is shown in Scheme 3. Racemic Diels-Alder adduct 27, which was formed by reacting methyl acrylate 26 with furan in the presence of ZnCl2 as Lewis acid catalyst, was dihydroxylated with H2O2 and catalytic osmium tetroxide with excellent exo-face selectivity. Acetonides 28 derived from the mixture of diastereoisomers 27 were treated with LHMDS in THF at −78°C to give methyl 5-epishikimate derivative 29 as a single product, whose hydroxyl group at C-5 was protected as silyl ether 30. Compound 30 was dihydroxylated with osumium tetroxide to give sole product 31 with the desired stereochemistry. After many examinations of regioselective O-methylation and O-acylation of 31, it was protected at C-2 by acetylation to give 32, then deprotected with 5-TBS ether to give alcohol 33, which in turn was oxidized with Dess-Martin periodinane to give β-hydroxyketone 34. α,β-Unsaturated ketone 35 obtained by adding TFAA to 34 was reduced with NaBH4 to give alcohol 36 with the desired stereochemistry of 37, followed by protection and deprotection. Alcohol 38 was oxidized with Dess-Martin periodinane to give unstable α,β-unsaturated enone 39, which could not be purified by silica gel chromatography. Crude 39 was reduced to generate hydroxyl group with the desired stereochemistry. However, not our objective reaction but an unexpected reaction occurred to yield 40. This work was published in 2004.
Garcia Ruano and co-workers reported their attempt to synthesize pericosine B in 2005. As shown in Scheme 4, asymmetric Diels-Alder cycloaddition reaction between chiral 3-sulfinylacrylonitrile 41 and furan with Me2AlCl as Lewis acid catalyst gave endo adduct 42 in 53% yield together with exo adduct in 10% yield [62]. The double bond in 42 was dihydroxylated exo-face selectively. The newly generated two hydroxyl groups were protected as acetonide 43, and this was converted into α,β-unsaturated nitrile 44 by basic treatment with NaNH2. Treatment with MeOH, followed by triethylamine and TMSOTf, afforded ring-opened nitrile 45, which seemed to be the last intermediate in the synthesis of 2. However, the subsequent transformation of cyano group into methoxycarbonyl group by methanolysis has not been reported so far.
3.2. Total synthesis of epimer of pericosine B: Synthesis of pericosine C [<xref ref-type="bibr" rid="b63-ijms-09-00401">63</xref>]
As described above, our synthesis of pericosine B could not be completed. Thus, we attempted to synthesize the epimer of pericosine B 7, as summarized in Scheme 5. Known methyl shikimate derivative 46 from (−)-quinic acid 11 was converted into TBS ether 47, which was reacted with catalytic osmium tetroxide and one equivalent of trimethylamine-N-oxide under reflux with tBuOH-pyridine-H2O (20:5:1) to give a mixture of diols 48 and 49 in 3:1 ratio in 40% yield with recovery of 47 (33%). Major diol 48 was selectively O-methylated at C-6 to give 50 in 66% yield as a single product, whereas minor diol 49 was singly 6-O-methylated to give 51 in 16% yield with 20% of 1,6-bis-O-methylated product. 6-O-Methyl ether 51 was further examined for its potential use in the synthesis of pericosine B 2, but all attempts were unsuccessful. Deprotection of methyl ether 50 with TBAF produced alcohol 51, and oxidation of 51 with Dess-Martin periodinane gave ketone 52, which in turn was dehydrated with TFAA to yield unsaturated ketone 53. Enone 53 was reduced with NaBH4 in excellent stereoselectivity to give alcohol 54, and this was then converted into target molecule (+)-7. When tested for in vitro for cytotoxicity against P388 cells, obtained (+)-7 gave an ED50 value of 17.8 μg/mL, which indicated lower activity than natural pericosine B (ED50: 4 μg/mL). Thus, we concluded that the stereochemistry of C-6 had a significant influence on cytotoxicity. When this work was published in 2004, synthesized (+)-7 was a non-natural product. However, it was elucidated later that (+)-7 had the same relative chemistry as natural pericosine A 1 and was a component of natural pericosine C, which is an enantiomeric mixture of 3 and 7 [55].
3.3. Total synthesis of initially assigned pericosines A and D [<xref ref-type="bibr" rid="b64-ijms-09-00401">64</xref>, <xref ref-type="bibr" rid="b65-ijms-09-00401">65</xref>]
After the publication of the total synthesis of pericosine B 2 by Donohoe, there had been no reports of pericosine A in spite of its antitumor activity. Then, the total synthesis of initially assigned pericosines A 6 and D 9 was attempted by our group because those two target compounds seemed to be synthesized via common intermediate enone 55 derived from (−)-quinic acid 11. Our retro-synthetic strategy is shown in Scheme 6. Key reactions of this synthesis included α-face selective chlorination of silylenolether derived from known ketone 59 [66, 67] and reagent-dependent stereoselective reduction of 55.
The synthesis of 6 was carried out as illustrated in Scheme 7. Lactone 59 derived from (−)-quinic acid 11 according to literature [66, 67] was chlorinated with NCS with excellent face selectivity to give α-chloroketone 58via silylenolether in 45% yield in 2 steps. The following reduction of 58 with NaBH4 gave alcohol 57 as the sole product. The chemical yield of 57 was improved by sequential reactions from 45% in 2 steps to an overall yield of 57% in 3 steps from ketone 59. Treatment of 57 with TFA in MeOH under reflux afforded tetraol 60 in 38% yield. Then, 60 was converted into acetonide 61, which was oxidized with Dess-Martin periodinane to give hydroxyketone 56. The isopropylidene moiety of 56 was removed with TFA because 56 could not be dehydrated by any dehydrating agents. One plausible explanation was that 56, conformationally fixed by an isopropylidene bridge, could not be transformed into a suitable transition state for dehydration. Resultant triol 62 was converted into reactive hydroxyketone 63 that was in turn dehydrated to enone 64 with Martin’s sulfrane dehydrating agent (bis[α,α-bis(trifluoromethyl) benzyloxy] diphenyl sulfur) [68] in 65% yield.
Treatment of enone 64 with TFA in MeOH gave 55, which was reduced stereoselectively with tetrabutylammonium triacetoxyborohydride [69] to afford 6 with the desired configuration as a single product. However, disagreement of the NMR data of 6 and acetonide 65 with those of natural pericosine A and those of its acetonide described in the literature [54] led us to conclude that the proposed stereochemistry of pericosine A was incorrect. Furthermore, the fact that “the isopropylidene bridge in 65 derived from 6 was located between C-4 and C-5, whereas that of the acetonide of pericosine A was between C-3 and C-4” [54] supported our conclusion.
Common intermediate 64 was reduced with NaBH4 to afford allyl alcohol 66 as a single product with opposite stereoselectivity. Then, 66 was deprotected to afford 9 quantitatively in 2 steps, as shown in Scheme 8. However, 9 was different from pericosine D. Then, product 9 was transformed into acetonide 67 to confirm the stereochemistry of the synthesized molecule.
The stereochemistry of all intermediates in this study was carefully determined by analyzing various kinds of 2D NMR spectra.
3.4. Total synthesis for structure revision and determination of absolute configuration of pericosine A [<xref ref-type="bibr" rid="b70-ijms-09-00401">70</xref>, <xref ref-type="bibr" rid="b71-ijms-09-00401">71</xref>]
From our conclusion in the previous study described in Section 3.3, determination of the true structure of pericosine A by total synthesis became our next task. In a comprehensive review of data related to pericosines [54, 63, 64], close similarity between the 1H-NMR coupling constants of natural pericosine A [54] and those of 7 [63] led us to deduce that the structure of natural pericosine A was 1, as illustrated in Figure 3.
Since 1 had the same relative chemistry as 7, our basic synthetic strategy was almost the same as that for 7. After a number of trials, the total synthesis of (−)-1 was achieved, as shown in Scheme 9. Known methyl 5-epishikimate derivative 68 derived from (−)-shikimic acid 9 was subjected to Dess-Martin oxidation to afford β,γ-unsaturated ketone 69. Without purification, 69 was reduced with NaBH4 to give alcohol (−)-70, which in turn was protected with TBSCl to give silyl ether 71. After dihydroxylation of 71, resultant diol 72 was acetylated to yield 73, and this was deprotected to give 74. Subsequent Dess-Martin oxidation of 74 gave β-hydroxyketone 75, which was dehydrated with TFAA to afford α,β-unsaturated ketone 76. Subsequent reduction of 76 was carried out carefully with stoichiometric NaBH4 at −78°C in dry THF to afford alcohol 77 possessing the desired stereochemistry in 95% yield.
Subsequent protection of 77 was carried out with careful addition of TBSCl and a stoichiometric amount of imidazole to give silyl ether 78 in 53% yield, followed by deacetylation with K2CO3 to afford enol 79 in 74% yield. The key reaction of this total synthesis, which was aimed at introducing a Cl atom, was achieved by the addition of excess SOCl2 to 79 in dry CH2Cl2 to afford chlorinated product 80 in 42% yield [71], whereas the yield of the reaction with stoichiometric SOCl2 was 10% [70]. To our surprise, 80 was formed with rearrangement of the double bond. The structure of key intermediate 80 was confirmed by detailed 1D and 2D NMR studies. In the NOESY spectra, cross peaks H-5/t-Bu, H-6/t-Bu, H-5/SiMe, H-6/SiMe, and H-3, H4/one of cyclohexyl methylenes, were observed. HMBC cross peak H-3, H-4/singlet carbon of 80, which was observed at 110.8 ppm, confirmed that the Cl atom was introduced not via an SNi mechanism as we had aimed early on, but via an SN2’ mechanism with syn selectivity. Another plausible mechanism is the [3,3]-sigmatropic rearrangement of chlorosulfonate derived from 79. In spite of detailed analysis of NMR spectra, the stereochemistry at C-6 in 80 could not be determined at this step. This total synthesis was completed with TFA to give final product (−)-1 in 66% yield, which was not 9 as synthesized previously by us [64, 65] but pericosine A. Thus, this result proved the stereochemistry at C-6 in 80. Except for the sign of the specific rotation, (−)-1 showed the same spectroscopic data, including HPLC retention time, as the natural product, and the absolute configuration of natural pericosine A was assigned as methyl (3S,4S,5S,6S)-6-chloro-3,4,5-trihydroxy-1-cyclohexene-1-carboxylate. The first total synthesis of the antipode of natural pericosine A was completed in this manner.
Next, the total synthesis of natural pericosine A (+)-1 was examined. As the preparation of (+)-70, which is an antipode in the preceding synthesis, from 11 has been reported, a similar strategy toward (−)-1 could be applicable. The synthesis of (+)-1 is summarized in Scheme 10 [71]. In our synthesis, the preparation of (+)-70 was modified from the original method appearing in the literature. Treatment of hydroxylactone 78 derived from 11 with NaOMe in MeOH followed by neutralization with DOWEX® 50W-X8 gave crude diol 79, which was obtained by only filtration and used in the next reaction without further extraction or purification. Diol 79 was oxidized to β-hydroxyketone 80, which was then dehydrated with TFAA to produce enone 81. Reduction with NaBH4 afforded enol 82 in 54% overall yield from 78. Enol 82 was converted into (+)-70 according to literature [72]. The following transformation of (+)-70 into (+)-1 was accomplished as above. Since all spectral data of synthesized (+)-1, including specific rotation and HPLC retention time, agreed with the data of natural pericosine A, the first synthesis of natural pericosine A was completed.
4. Further Discussion
As described above, pericosines are interesting compounds because of their potent biological activities and unique structures. In particular, the role of pericosine A 1 in anti-tumor, protein kinase EGFR inhibition or topoisomerase II inhibition was demonstrated. In terms of chemical structure, the relative chemistry of pericosines A 1, C 3, and B 2 is so unique that it is difficult to find the same configurational carbasugar natural products, whereas pericosine D 4 has the same relative configuration as (+)-MK7607. We are extremely interested in the fact that pericosines C 3 and E 5 exist as an enantiomeric mixture. How are they biologically formed? Pericosine E 5 is thought to be a conjugate of pericosines A 1 and B 2 but with different chiral sense. This suggests the possibility of the presence of antipodes of 1 and 2 or unknown analogues with other combinations. We are currently directing our efforts toward designing a more effective synthetic route for pericosine A 1 because of the low total yield in our completed first synthesis. Nevertheless, the SN2’ type reaction, which is the key step for Cl introduction in our previous work [70, 71], may help unravel the mystery surrounding the chirality of percosines. A reaction similar to this or the enantioselective dehydration from prochiral 3-epiquinate may occur in fungal metabolic systems to generate chirality. Indeed, it seems unbelievable that enantiomeric mixtures of 3 and 5, particularly 5 that bears 8 chiral centers, could be formed biologically. In that sense, pericosines are truly exciting compounds.
On the other hand, we would like to point out the ambiguity of the conformation of pericosines. It is absolutely difficult to determine the configuration or conformation of pericosines only from spectral analysis. 1H-NMR coupling constants of pericosines and acetonides are shown in Figure 4. The correct structure of 1 could not be concluded only from the synthesis of 1. The stereochemistry of C-6 in intermediate 80 could be determined not from detailed spectral analysis but from the difference between deprotected 1 and 9, the latter of which was synthesized in our previous study [64, 65]. We hope to solve this problem by integrating our vast synthetic efforts with data from other researchers.
The synthetic study of pericosine D is ongoing in an effort to determine its absolute configuration [73]. After elucidating all the structures of pericosines, we will examine the biological activity of synthesized pericosine analogues, develop more effective synthetic routes, and design more active molecules based on these seed compounds.
Acknowledgements
We are grateful to Dr. K. Minoura and Ms. M. Fujitake, and Dr. Takeshi Yamada of Osaka University of Pharmaceutical Sciences for NMR and MS measurements, and discussion concerning pericosines, respectively. This work was supported in part by a Grant-in-Aid for “High-Tech Research Center” Project for Private Universities: matching fund subsidy from MEXT (Ministry of Education, Culture, Sports, Science, and Technology), 2002–2006, Japan.
References and NotesSuamiTSynthetic ventures in pseudo-sugar chemistryPure Appl Chem19875915091520DOI 10.1351/pac19875911150910.1351/pac198759111509BerecibarAGrandjeanCSinwardenaASynthesis and Biological Activity of Natural Aminocyclopentitol Glycosidase Inhibitors: Mannostatins, Trehazolin, Allosamidins, and Their AnalogsChem Rev199999779844DOI 10.1021/cr980033l; PubMed 1174943210.1021/cr980033l11749432ArjonaOGomezAMLopezJCPlumetJSynthesis and conformational and biological aspects of carbasugarsChem Rev200710719192036DOI 10.1021/cr0203701; PubMed 1748806010.1021/cr020370117488060MirzaSMolleyresLPVasellaASynthesis of a glyoxalase I inhibitor from Streptomyces griseosporeus Niida et OgasawaraHelvetica Chimica Acta198568988996DOI 10.1002/hlca.1985068042510.1002/hlca.19850680425TakayamaHHayashiKKoizumiTEnantioselective total synthesis of glyoxalase I inhibitor using asymmetric Diels-Alder reaction of a new chiral dienophile, (S)S-3-(3-trifluoromethylpyrid-2-ylsulfinyl)acrylateTetrahedron Lett19862755095512DOI 10.1016/S0040-4039(00)85252-110.1016/S0040-4039(00)85252-1YamakoshiYNakajimaYGeW-YSugitaJOkayamaKTakahashiTKoizumiTHigh pressure mediated asymmetric Diels-Alder reaction of chiral sulfinylacrylate derivatives with furan and 2-methoxyfuranHeterocycles19964212913310.3987/COM-95-S43TakahashiTYamakoshiYOkayamaKYamadaJGeW-YKoizumiTHigh-pressure mediated asymmetric Diels-Alder reaction of chiral sulfinylacrylate derivatives and its application to chiral synthesis of (−)-COTC and (−)-gabosine CHeterocycles20025620922010.3987/COM-01-S(K)18ArthursCLWindNSWhiteheadRCStratfordIJAnalogues of 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) with anti-tumor propertiesBioorg & Med Chem Lett200717553557DOI 10.1016/j.bmcl.2006.09.07210.1016/j.bmcl.2006.09.072ArthursCLRafteryJWhitbyHLWhiteheadRCWindNSStratfordIJArene cis-dihydrodiols: Useful precursors for the preparation of analogs of the antitumor agent, 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC)Bioorg & Med Chem Lett20071759745977DOI 10.1016/j.bmcl.2007.07.07010.1016/j.bmcl.2007.07.070RamanaaGVRaoBVStereoselective synthesis of (−)-gabosine C using a Nozaki-Hiyama-Kishi reaction and RCMTetrahedron Lett20054630493051DOI: 10.1016/j.tetlet.2005.03.01810.1016/j.tetlet.2005.03.018HuntleyCFMWoodHBGanemBA new synthesis of the glyoxalase-I inhibitor COTCTetrahedron Lett20004120312034DOI 10.1016/S0040-4039(00)00103-910.1016/S0040-4039(00)00103-9HuntleyCFHamiltonDSCreightonDJGanemBReaction of COTC with glutathione: structure of the putative glyoxalase I inhibitorOrg Lett2000231433144DOI 10.1021/ol006341z; PubMed 1100936610.1021/ol006341z11009366ShingTTangYEnantiospecific synthesis of 2-crotonyloxy-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enone (COTC) from quinic acidJ Chem Soc, Chem Commun1990312ShingTTangY(−)-Quinic acid in organic synthesis. 1. A facile synthesis of 2-crotonyloxymethyl-(4R,5R,6R)-4,5,6-trihydroxycyclohex-2-enoneTetrahedron1990466575658410.1016/S0040-4020(01)96022-3TatsutaKYasudaSArakiNTakahashiMKamiyaYTotal synthesis of a glyoxalase I inhibitor and its precursor, (−)-KD16-U1Tetrahedron Lett199839401402DOI 10.1016/S0040-4039(97)10559-710.1016/S0040-4039(97)10559-7ShinadaTFujiTOhtaniYYoshidaYOhfuneYSyntheses of gabosine A, B, D, and E from allyl sulfide derived from (−)-quinic acidSynlett200213411343LygoBSwiatyjMTrabsaHVoyleMSynthesis of (+)-Gabosines C and E from D-ribose Tetrahedron Lett19943541974200DOI (Either ISSN and Title must be supplied)BanwellMGBrayAMWongDA concise and chemo-enzymatic synthesis of (−)-gabosine A, a carba-sugar enone from StreptomycetesJ New J Chem2001251351135410.1039/b106419cLubineauABillaultINew Access to Unsaturated Keto Carba Sugars (Gabosines) Using an Intramolecular Nozaki-Kishi Reaction as the Key StepJ Org Chem1998635668567110.1021/jo980309pAlibesRBayonPDe MarchPFigueredoMFontJMarjanetGEnantioselective synthesis and absolute configuration assignment of gabosine O. Synthesis of (+)- and (−)-gabosine N and (+)- and (−)-epigabosines N and OOrganic Lett200681617162010.1021/ol060173eShingTKMChengHMShort Syntheses of Gabosine I and Gabosine G from δ-D-GluconolactoneJ Org Chem20077266106613DOI 10.1021/jo0709697; PubMed 1763706710.1021/jo070969717637067MehtaGLakshminathSA norbornyl route to cyclohexitols: stereoselective synthesis of conduritol-E, allo-inositol, MK 7607 and gabosinesTetrahedron Lett20004135093512DOI 10.1016/S0040-4039(00)00409-310.1016/S0040-4039(00)00409-3SongCJiangSSinghGSynthesis of (−)-MK7607 and Other Carbasugars from (−)-shikimic AcidSynlett200119831985SchmidtRRKoenAα-Glucosidase inhibitors. Part 4. Synthesis of valienamineAngew Chem19879949049110.1002/ange.19870990529ParkTKDanishefskySJA synthetic route to valienamine: an interesting observation concerning stereoelectronic preferences in the SN2’ reactionTetrahedron Lett19943526672670DOI 10.1016/S0040-4039(00)77001-810.1016/S0040-4039(00)77001-8FukaseHHoriiSSynthesis of a branched-chain inosose derivative, a versatile synthon of N-substituted valiolamine derivatives from D-glucoseJ Org Chem19925736513658DOI 10.1021/jo00039a02610.1021/jo00039a026TrostBMChupakSLuebbersTTotal Synthesis of (±)- and (+)-Valienamine via a Strategy Derived from New Palladium-Catalyzed ReactionsJ Am Chem Soc199812017321740DOI 10.1021/ja973081g10.1021/ja973081gShingTKMLiTYKokSH-LEnantiospecific Syntheses of Valienamine and 2-epi-ValienamineJ Org Chem19996419411946DOI 10.1021/jo982024i; PubMed 1167428610.1021/jo982024i11674286YoshikawaMChaBCOkaichiYTakinamiYYokokawaYKitagawaISyntheses of validamine, epi-validamine, and valienamine, three optically active pseudo-amino-sugars, from D-glucoseChem Pharm Bull1988364236423910.1248/cpb.36.4236TatsutaKMukaiHTakahashiMNovel synthesis of natural pseudo-aminosugars, (+)-valienamine and (+)-validamineJ Antibiot200053430435PubMed 1086622710.7164/antibiotics.53.43010866227ChangY-KLeeB-YLeeGSJeonHBKimKSAn Efficient Synthesis of Valienamine via Ring-Closing MetathesisJ Org Chem20057032993302PubMed 1582300010.1021/jo047735x15823000von ItzsteinMWuWYKokGBPeggMSDyasonJCJinBVanPTSmytheMLWhiteHFOliverSWColmanPMVargheseJNRyanDMWoodsJMBethellRCHothamVJCameronJMPennCR Rational design of potent silalidase-based inhibitors of influenza virus replicationNature1993363418423PubMed 850229510.1038/363418a08502295KimCULewWWilliamsMAZhangLLiuHSwaminathanSBischofbergerNChenMSTaiCYMendelDBLaverWGStevensRCInfluenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activityJ Am Chem Soc1997119681690DOI 10.1021/ja963036t; PubMed 1652612910.1021/ja963036t16526129RohloffJCKentKMPostichMJBeckerMWChapmanHHKellyDELewWLouieMSMcGeeLRPrisbeEJSchultzeLMYuRHZhangLPractical Total Synthesis of the Anti-Influenza Drug GS-4104J Org Chem19986345454550DOI 10.1021/jo980330q10.1021/jo980330qYeungY-YHongSCoreyEJA Short Enantioselective Pathway for the Synthesis of the Anti-Influenza Neuramidase Inhibitor Oseltamivir from 1,3-Butadiene and Acrylic AcidJ Am Chem.Soc200612863106311DOI 10.1021/ja0616433; PubMed 1668378310.1021/ja061643316683783FukutaYMitaTFukudaNKanaiMShibasakiMCatalytic Asymmetric Total Synthesis of (+)-LactacystinJ Am Chem Soc200612863126313PubMed 1668378410.1021/ja061696k16683784MitaTFukudaNRocaFXKanaiMShibasakiMSecond generation catalytic asymmetric synthesis of Tamiflu: allylic substitution routeOrg Lett20079259262DOI 10.1021/ol062663c; PubMed 1721727910.1021/ol062663c17217279SatohNAkibaTYokoshimaSFukuyamaTA practical synthesis of (−)-oseltamivirAngewandte Chem, Int Ed20074657345736DOI 10.1002/anie.20070175410.1002/anie.200701754KarchierMMichalakKWichaJAnti-influenza drugs Synthesis of Tamiflu, a drug kept in stock to prevent a bird flu epidemicWiadomosci Chemiczne200761742ShieJ-JFangJ-MWangS-YTsaiK-CChengY-SEYangA-SHsiaoS-CSuC-YWongC-HSynthesis of Tamiflu and its Phosphonate Congeners Possessing Potent Anti-Influenza ActivityJ Am Chem Soc20071291189211893DOI 10.1021/ja073992i; PubMed 1785008310.1021/ja073992i17850083TakeuchiTChimuraHHamadaMUmezawaHYoshiokaOOguchiNTakahashiYMatsudaAGlyoxalase I inhibitor of a new structural type produced by StreptomycesJ Antibiot197528737742PubMed 110251010.7164/antibiotics.28.7371102510TatsutaKTsuchiyaNMikamiNUmezawaSUmezawaHNaganawaHKD16-U1, a new metabolite of Streptomyces. Isolation and structural studiesJ Antibiot197427579586PubMed 443614310.7164/antibiotics.27.5794436143BachGBreiding-MackSGrableySHammannPHutterKThierickeRUhrHWinkJZeeckASecondary metabolites by chemical screening. 22. Gabosines, new carba-sugars from StreptomycesLiebigs Ann Chem1993241250YoshikawaNChibaNMikawaTUenoSHarimayaKIwataMNovel herbicidal MK7607 and its manufacture with CurvulariaJpn Kokai Tokkyo Koho JP199406306000HoriiSIwasaTMizutaEKamedaYValidamycins, new antibiotics. VI. Validamine, hydroxyvalidamine, and validatol, new cyclitolsJ Antibiot1971245963PubMed 554133510.7164/antibiotics.24.595541335KamedaYHoriiSStructure of the antibiotic validamycin AJ Chem Soc, Chem Commun1972746747SuamiTOgawaSChidaNThe revised Structure of Validamycin AJ Antibiot1980339899PubMed 737256010.7164/antibiotics.33.987372560LaubeHFouladfarMAubellRSchmitzHEffect of glucosidase inhibitor, Bay g 5421 (acarbose), on the blood glucose in obese diabetic patients type 2 (NIDDM)Arzneimittel-Forschung19803011541157PubMed 71912997191299MooreRECorbettTHPattersonGMLValerioteFAThe search for new antitumor drugs from blue-green algaeCurrent Pharmaceutical Design19962317330NewmanDJCraggGMNatural Products as Sources of New Drugs over the Last 25 YearsJ Nat Prod200770461477PubMed 1730930210.1021/np068054v17309302FenicalWJensenPRDeveloping a new resource for drug discovery: marine actinomycete bactereiaNature Chemical Biology20062666673DOI 10.1038/nchembio841; PubMed 1710898410.1038/nchembio84117108984NewmanDJCraggGMNatural products from marine invertebrates and microbes as modulators of antitumor targetsCurrent Drug Targets20067279304DOI 10.2174/138945006776054960; PubMed 1651552810.2174/13894500677605496016515528NewmanDJHillRTNew drugs from marine microbes: the tide is turningJ Ind Microbiol Biotechnol200633539544DOI 10.1007/s10295-006-0115-2; PubMed 1659849310.1007/s10295-006-0115-216598493NumataAIritaniMYamadaTMinouraKMatsumuraEYamoriTTsuruoTNovel antitumor metabolites produced by a fungal strain from a sea hareTetrahedron Lett19973882158218DOI 10.1016/S0040-4039(97)10198-810.1016/S0040-4039(97)10198-8YamadaTIritaniMOhishiHTanakaKDoiMMinouraKNumataAPericosines, antitumor metabolites from the sea hare-derived fungus Periconia byssoides. Structures and biological activitiesOrg Bioorg Chem200753979398610.1039/b713060kYamadaTMinouraKNumataAInProc. of the 119th Annual Meeting of the Pharmaceutical Society of JapanTokushima, Japan1999Abstract 2159YamadaTPh. D. ThesisOsaka University of Pharmaceutical SciencesJapan2002DonohoeTJBladesKHelliwellMWaringMJNewcombeNJThe Total Synthesis of (+)-Pericosine BTetrahedron Lett19983987558758DOI 10.1016/S0040-4039(98)01989-310.1016/S0040-4039(98)01989-3OkamuraHNakamuraYMorishigeKOhuraRShimizuHIwakawaTNakataniMDevelopment of Base Catalized Diels-Alder Reaction of 3-Hydroxy-2-pyrone and its Application to Synthesis of Biologically Active Compounds40th Tennen Yuki Kagobutsu Toronkai Koen YoshisyuFukuoka, Japan1988187192UsamiYNumataAExamination of the reactivities of hydroxy groups in multioxygenated cyclohexanoids: Synthetic study toward cytotoxic pericosine BChem Pharm Bull20045211251129DOI 10.1248/cpb.52.1125; PubMed 1534020310.1248/cpb.52.112515340203Garcia RuanoJAlemparteCLopez-CantareroJ(Z)-3-p-Tolylsulfinylacrylonitrile as a Chiral Dienophile: Diels-Alder Reactions with Furan and Acyclic DienesJ Org Chem20006579387943DOI 10.1021/jo000963g; PubMed 1107360110.1021/jo000963g11073601Garcia RuanoJLopez-CantareroJMartin CastroAMAdamsHRogriguez RamosJHtoward the Synthesis of (+)-Pericosine BPhosphorus, Sulfur and Silicon and the Related Elements200518014931494DOI 10.1080/1042650059091333910.1080/10426500590913339UsamiYHatsunoCYamamotoHTanabeMNumataASynthesis of the epimer of pericosine B from (−)-quinic acidChem Pharm Bull20045211301133PubMed 1534020410.1248/cpb.52.113015340204UsamiYUedaYSynthetic Study toward Antitumour Natural Product Pericosine AChem Lett20053410621063DOI 10.1246/cl.2005.106210.1246/cl.2005.1062UsamiYUedaYStereoselective Syntheses of Diastereomers of Antitumor Natural Product Pericosine A from (−)-Quinic AnidSynthesis200732193225MantheyMKGonzalez-BelloCAbellCSynthesis of (2R)-2bromodehydroquinic acid and (2R)-2fluorodehydroquinic acidJ Chem Soc, Perkin Trans1997625628Gonzalez-BelloCMantheyMKHarrisJHHawkinsARCogginsJRAbellCSynthesis of 2-Bromo- and 2-Fluoro-3-dehydroshikimic Acids and 2-Bromo- and 2-Fluoroshikimic Acids Using Synthetic and Enzymic ApproachesJ Org Chem1998631591159710.1021/jo971858iAlhaltRJMartinJCSulfuranes. VI. Reactions involving the alkoxy ligands of dialkoxydiarylsulfuranes. Formation of olefins and ethersJ Am Chem Soc1972945003501010.1021/ja00769a036EvansDAChapmanKTThe directed reduction of β-hydroxy ketones employing Me4NHB(OAc)3Tetrahedron Lett19862759395942DOI 10.1016/S0040-4039(00)85367-810.1016/S0040-4039(00)85367-8UsamiYHoribeYTakaokaIIchikawaHArimotoMFirst Total Synthesis of (−)-Pericosine A from (−)-Shikimic Acid: Structure Revision and Determination of the Absolute Configuration of Antitumor Natural Product Pericosine ASynlett200615981600UsamiYTakaokaIIchikawaHHoribeYTomiyamaSOhtsukaMImanishiYArimotoMFirst Total Synthesis of (+)- and (−)-Pericosine A: Determination of Absolute Stereo StructureJ Org Chem20077261276134PubMed 1762810610.1021/jo070715l17628106UlibarriGNadlerWSkrydstrupTAudrainHChianoriARicheCGriersonAAConstruction of the Bicyclic Core Structure of the Enediyne Antibiotic Esperamicin-A1 in Either Enantiomeric Form from (−)-Quinic AcidJ Org Chem1995602753276110.1021/jo00114a025UsamiYMizukiKIchikawaHArimotoMInProc. of the 57th Annual Meeting of the Pharmaceutical Society of Japan Kinki-branchOsaka, Japan200736Figures and Table
Structures of bioactive carbasugars as synthetic targets.
Structures of pericosines and analogues.
Comparison of coupling constants between epimer of pericosine B 7 and pericosine A 1.
Coupling constants in Hz observed in 1H-NMR spectra of pericosines and their analogues.
Successful total synthesis of (+)-pericosine B by Donohoe and co-workers.